IL6 and type 2 diabetes mellitus: The Glinide group of drugs exhibit mechanisms similar to that of the sulfonylureas; Mitiglinide has demonstrated some reduction in oxidative stress levels and inflammatory markers IL-6, IL-18, and TNF-a in T2DM, but studies of clinical neurologic effects are lacking (140).